Narcotic drug for cancer-related distress

Narcotic drug for cancer-related distress

There is no shortage of treatment options for cancer, from radiotherapy and chemotherapy to experimental options such as immunotherapy. However, despite all the research and experience on the disease itself, there are relatively few options for treating cancer. Myself effects. These invisible diseases occur with enough frequency that there is a name for them – malaise associated with cancer.

In a recent survey published in the American Society of Clinical Oncology Journal, nearly 30 percent of patients reported symptoms that were identified as “clinically meaningful.” Reported psychological problems included fatigue, anxiety, insomnia, sadness, nervousness, fear and memory problems. Physiological symptoms included tingling, skin problems, appearance problems and pain.

It is no coincidence that many of these symptoms have also been linked to severe stress. Cancer-related distress is very likely to be a stress response to disease, exacerbated by the isolation that often accompanies treatment.

In severe cases, patients with this condition have been known to become disabled due to feelings of depression, anxiety, and panic. Those with the psychological disorders that often accompany cancer can question the meaning and purpose of one’s life – known as existential or spiritual crises. Unfortunately, many of the treatment options that are usually applied to these conditions are either ineffective or unavailable in cases of cancer-related distress.

painful truth

It doesn’t mean that cancer patients lack a way to get mental health support. There are therapists and counselors who specialize in cancer-related distress and frequently work with oncologists. The problem is that in many cases, counseling is simply not enough.

A patient in particularly severe distress may require drug options in addition to treatment. Unfortunately, depending on the medications prescribed to treat the disease, oncologists may choose to forgo antidepressants or anti-anxiety medications. To some extent, this is completely understandable.

For example, many antidepressants have a documented history of contraindications when interacting with chemotherapy drugs. Studies show that standard selective serotonin reuptake inhibitors (SSRIs), a first-line approach to mental health problems in healthy patients, can compromise the effectiveness of chemotherapy or the risks of fatal interactions with other cancer drugs.

One can hardly blame the doctor for not wanting to put the patient’s life at risk. At the same time, one must admit that mental health is just as important as physical well-being.

As it stands, there is often a shortage of pharmaceutical treatments for cancer-related distress – it’s an unmet need.

Why fall short of standard mental health treatments for cancer patients

Therapists and psychologists may not always be equipped to help patients manage the complex fears and emotions that come with cancer. With this in mind a specialized field emerged. Known as psycho-oncology, psycho-oncology, psycho-oncology, or supportive care services, this specialty includes people with multiple backgrounds, from psychologists to psychiatrists to chaplains.

According to the American Psychosocial Oncology Society, psychosocial oncology addresses the psychological, emotional, social, and behavioral challenges that cancer patients face alongside their loved ones. It primarily focuses on helping patients treat their cancer-related distress. However, it also examines the underlying factors that may influence cancer-related distress or make adjustment more difficult.

Although psychiatrists or nurse practitioners who specialize in psycho-oncology may choose to offer patients pharmaceutical treatments, this will not always be the case. This goes back to two issues. The first is the relative lack of drugs without possible contraindications.

Second, perhaps the most pressing issue is the fact that cancer-related distress, while it may overlap or share symptoms with diagnosed mental illnesses, is a distinct condition in its own right. It manifests itself more often in patients who are otherwise of a neurogenic type. These patients represent another category for which treatment and advice alone is likely to be inappropriate.

Here narcotic treatments appear as a viable alternative.

The way forward with the drug

Over the past several years, there have been many studies and clinical trials examining the effect of psilocybin on mental illnesses such as anxiety and depression. For example, a recent study by Johns Hopkins Medicine gave a small group of adults with major depression two doses of the substance paired with supportive psychotherapy.

The majority of patients experienced a significant and rapid reduction in depressive symptoms, with approximately half showing no signs of depression over the course of the four-week follow-up programme.

“The effect size we saw was about four times larger than what clinical trials of conventional antidepressants on the market have shown,” explained Alan Davis, PhD, assistant professor of psychiatry and behavioral sciences at Johns Hopkins University School of Medicine, “because most other depression treatments take weeks to complete.” Or months until they work and may have unwanted effects, this could be a game-changer if these results hold up in future ‘gold standard’ placebo-controlled clinical trials.”

Multiple studies have been conducted on the effectiveness of psilocybin as a treatment option for cancer-related distress. They almost universally conclude that the drug shows great promise. However, these experiments, despite their tight controls, do not paint a complete picture.

They demonstrate that the drug may be effective in a clinical setting, yet cannot take into account real-world factors. These include, but are not limited to, changing treatment patterns, long-term patient safety and affordability. These clinically meaningful data are essential in the face of a changing healthcare landscape – with modern care increasingly focused on personalization, randomized trials alone are no longer sufficient.

Researchers must try to understand how a drug behaves under complex and unpredictable conditions. Furthermore, they must pursue an alternative to the years (or sometimes decades) long approval process for new treatments. In the case of psilocybin, it may also help to overcome the needless stigma under which narcotic drugs are currently operating.

Albert Labs (CSE: ABRT) is one of the companies dedicated to generating such evidence. The company is currently focused on developing a psilocybin-based drug for patients experiencing cancer-related distress. Albert Labs has an existing relationship with Europe’s largest oncology center, which will allow the company to rapidly spread its innovative treatment for cancer patients.

In an interview, Dr. Malcolm Barratt-Johnson, chief medical officer of Albert Labs, said, “We look at depression and anxiety in cancer patients. We haven’t studied this area much in the past 20-30 years because of the interaction that many antidepressants have in cancer patients. Using psilocybin, we can look at this group because the potential risks of interaction are much lower.”


Unfortunately, hallucinogens are still demonized in many circles, although their negative reputation is largely based on hearsay. Real-world evidence from clinical trials suggests that medications such as psilocybin can be very helpful in relieving not only stress but also symptoms of many mental illnesses. Most importantly, they can achieve this with the least amount of harmful side effects.

This INNspired article is sponsored by Albert Labs (CSE: ABRT). This article INNspired provides information obtained from Investment News Network (INN) and approved by Albert LaboratoriesTo help investors learn more about the company. Albert Laboratories He is an INN client. A company campaign fee is paid to INN to create and update this article INNspired.

This INNspired article has been written in accordance with the INN Editorial Standards for investor education.

INN does not provide investment advice and the information in this profile should not be considered a recommendation to buy or sell any security. INN does not endorse or recommend the businesses, products, services, or securities of any identified company.

The information herein is for informational purposes only and should not be construed as an offer or solicitation to sell or buy securities. Readers should do their own research for all publicly available information related to the company. Before making any investment decision, it is recommended that readers consult directly with Albert LaboratoriesSeek advice from a qualified investment advisor.

2022-06-01 20:03:29

Leave a Comment

Your email address will not be published.